1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hypercholesterolemia - Drugs In Development, 2022, provides an overview of the Hypercholesterolemia (Metabolic Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. This leads in formation of sticky deposits (called plaque) along the artery walls. Plaque can completely block blood flow through an artery, causing heart attack or stroke. Two forms of the condition exist heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). Risk factors include obese, family history, high blood pressure, smoking and diabetes. Treatment includes statins, bile acid sequestrants, fibric acid derivatives and cholesterol absorption inhibitors
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Hypercholesterolemia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 18, 16, 14, 4, 27, 10 and 6 respectively. Similarly, the Universities portfolio in Phase 0, Preclinical and Discovery stages comprises 1, 8 and 1 molecules, respectively.
Hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypercholesterolemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypercholesterolemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Hypercholesterolemia - Overview
- Hypercholesterolemia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Hypercholesterolemia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hypercholesterolemia - Companies Involved in Therapeutics Development
- Hypercholesterolemia - Drug Profiles
- Hypercholesterolemia - Dormant Projects
- Hypercholesterolemia - Discontinued Products
- Hypercholesterolemia - Product Development Milestones
- Featured News & Press Releases
- Sep 23, 2022: Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia
- Sep 21, 2022: Verve Therapeutics announces clearance of clinical trial authorisation application by the United Kingdom Medicines and Healthcare Products Regulatory Agency for VERVE-101 in patients with heterozygous familial hypercholesterolemia
- Sep 13, 2022: MediciNova receives a notice of allowance for a new patent covering MN-001 and MN-002 for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia in Canada
- Aug 29, 2022: New Amgen data at ESC 2022 show long-term LDL-C lowering with REPATHA (evolocumab) was well-tolerated for more than 8 years
- Aug 29, 2022: NewAmsterdam Pharma showcases leadership in cardiometabolic disease treatment in multiple presentations at ESC congress 2022
- Aug 29, 2022: Verve Therapeutics highlights preclinical data supporting nomination of VERVE-201 ANGPTL3 product candidate at the European Society of Cardiology 2022 Congress
- Aug 29, 2022: AMGEN to present new data at ESC Congress 2022 highlighting up To 8.5 years of Repatha (Evolocumab) safety and tolerability data in high-risk ASCVD patient populations
- Aug 29, 2022: Latest simulation analyses from the SANTORINI registry indicates that adding bempedoic acid in the lipid lowering treatment algorithm might help more patients achieve LDL-C recommended goals
- Aug 02, 2022: Vaxxinity’s anti-PCSK9 candidate demonstrates durable LDL cholesterol lowering in non-human primates
- Jul 28, 2022: NewAmsterdam pharma doses first patient in phase 3 BROOKLYN clinical trial evaluating obicetrapib in patients with heterozygous familial hypercholesterolemia
- Jul 12, 2022: Verve Therapeutics doses first human with an investigational in vivo base editing medicine, VERVE-101, as a potential treatment for heterozygous familial hypercholesterolemia
- Jun 29, 2022: Nyrada announces update on Cholesterol-Lowering Program
- Jun 13, 2022: Innovent announces the NMPA acceptance of the New Drug Application for Tafolecimab Injection (anti-PCSK-9 antibody)
- May 31, 2022: First Subject dosed in Lipigon’s phase I clinical study with antisense oligonucleotide Candidate Derived from Secarna Pharmaceutical’s LNAplus(TM) Technology Platform
- May 21, 2022: Evkeeza (evinacumab) phase 3 trial demonstrates 48% LDL-C reduction in children with ultra-rare form of high cholesterol
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Hypercholesterolemia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Hypercholesterolemia - Dormant Projects, 2022
- Hypercholesterolemia - Discontinued Products, 2022
- Number of Products under Development for Hypercholesterolemia, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- Addpharma Inc
- AFFiRiS AG
- Akcea Therapeutics Inc
- Akeso Inc
- Alexion Pharmaceuticals Inc
- Amgen Inc
- Amryt Pharma Plc
- Amytrx Therapeutics Inc
- Arrowhead Pharmaceuticals Inc
- Astellas Pharma Inc
- AstraZeneca Plc
- Beijing Mabworks Biotech Co Ltd
- BioLingus AG
- Bo Jiyuan (Chongqing) Pharmaceutical Technology Co Ltd
- Boryung Pharmaceutical Co Ltd
- CardioPharma Inc
- Centeer BioTherapeutics Ltd Co
- Chong Kun Dang Pharmaceutical Corporation
- Civi Biopharma Inc
- Daewon Pharmaceutical Co Ltd
- Daewoong Pharmaceutical Co Ltd
- Delivra Corp
- Draupnir Bio Aps
- Eight Plus One Pharmaceutical Co Ltd
- Epicrispr Biotechnologies Inc
- Esperion Therapeutics Inc
- Golden Biotechnology Corp
- Gruthan Bioscience LLC
- Guangzhou Jiayue Pharmaceutical Technology Co Ltd
- Haisco Pharmaceutical Group Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- Hanmi Science Co Ltd
- Hingez Therapeutics Inc
- Huons Co Ltd
- Imagine Pharma LLC
- iMetabolic Biopharma Corp
- Innovent Biologics Inc
- Jiangsu Carephar Pharmaceutical Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Kyorin Pharmaceutical Co Ltd
- Kyttaro Ltd
- LIB Therapeutics LLC
- Lipigon Pharmaceuticals AB
- LipimetiX Development Inc
- Luckwel Pharmaceuticals Inc
- Luye Pharma Group Ltd
- Lyndra Therapeutics Inc.
- Mab-Science (Hong Kong) Co Ltd
- Medlab Clinical Ltd
- Merck & Co Inc
- NeuroBo Pharmaceuticals Inc
- NewAmsterdam Pharma BV
- NorthSea Therapeutics BV
- Novartis AG
- Novo Nordisk AS
- Nyrada Inc
- OliPass Corporation
- Orient Pharma Co Ltd
- Precision Biosciences Inc
- Progenra Inc
- Regeneron Pharmaceuticals Inc
- RegenxBio Inc
- Repair Biotechnologies Inc
- Saliogen Therapeutics Inc
- Sanofi
- Seed Health Inc
- Shandong Boan Biotechnology Co Ltd
- Shanghai Henlius Biotech Inc
- Shanghai Junshi Bioscience Co Ltd
- Shenzhen Salubris Pharmaceuticals Co Ltd
- Shifa Biomedical Corp
- Sirnaomics Ltd
- Vaxxinity Inc
- Verve Therapeutics Inc
- Viking Therapeutics Inc
- Zhejiang Teruisi Pharmaceutical Co Ltd
